NPM1 and acute myeloid leukemia: These findings underscore the necessity for age-adapted risk stratification in NPM1-mutated AML, which could prevent potential overestimation of prognosis in older patients and inform more appropriate therapeutic decision making, ultimately improving clinical outcomes.